Jan-Paul Bohn
Overview
Explore the profile of Jan-Paul Bohn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
115
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bohn J, Stolzlechner V, Gobel G, Willenbacher W, Pirklbauer M, Steiner N, et al.
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594701
: Elevated beta-2-microglobulin (B2M) plasma levels commonly imply a higher CLL-IPI risk category for short overall survival (OS), but the risk model was not adjusted for compromised kidney function and...
2.
Bohn J, Stolzlechner V, Gobel G, Pirklbauer M, Wolf D, Steiner N
Leuk Lymphoma
. 2024 Aug;
65(14):2108-2115.
PMID: 39165182
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults and characterized by a highly heterogeneous clinical course. The CLL-IPI and the OCLL-1 scores are among the best validated...
3.
Prantl L, Heider P, Bergmeister L, Calana K, Bohn J, Wolf D, et al.
Front Immunol
. 2024 Aug;
15:1379023.
PMID: 39104533
Antibody-mediated complement-dependent cytotoxicity (CDC) on malignant cells is regulated by several complement control proteins, including the inhibitory complement factor H (fH). fH consists of 20 short consensus repeat elements (SCRs)...
4.
Plattner C, Sallaberger S, Bohn J, Zavadil C, Keller F, Soleiman A, et al.
Clin Kidney J
. 2024 May;
17(5):sfae109.
PMID: 38726211
Background: The development of chronic kidney disease (CKD) in about 20%-40% of patients with type 2 diabetes (T2D) aggravates cardiovascular morbidity and mortality. Pathophysiology is of increasing relevance for individual...
5.
Simon F, Bohn J
Curr Oncol Rep
. 2023 Sep;
25(10):1181-1189.
PMID: 37682487
Purpose Of Review: This research paper aims to provide an overview of evidence-based sequencing of therapies in relapsed/refractory chronic lymphocytic leukemia (CLL) in the era of targeted drugs. Recent Findings:...
6.
Chihara D, Gras L, Zinger N, Kroger N, Mayer J, Passweg J, et al.
Haematologica
. 2022 Dec;
108(6):1676-1679.
PMID: 36546416
No abstract available.
7.
Bohn J, Fiala A, Bachmann S, Irsara C, Wolf D, Feistritzer C
Ther Adv Hematol
. 2022 Aug;
13:20406207221104595.
PMID: 35923771
The introduction of extended factor IX (FIX) products has significantly facilitated the treatment of hemophilia B patients. However, optimal perioperative management remains a topic of hot debate, particularly in surgeries...
8.
Bohn J
Memo
. 2022 Apr;
15(2):121-124.
PMID: 35437451
The treatment landscape of chronic lymphocytic leukemia (CLL) has undergone profound change in recent years. Targeted therapies have outnumbered chemotherapy-based treatment approaches demonstrating superior efficacy and tolerability profiles across nearly...
9.
Bohn J, Neururer S, Pirklbauer M, Pircher A, Wolf D
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267550
Classic hairy cell leukemia (HCL) is an uncommon hematologic malignancy characterized by an excellent prognosis since purine analogues (PA), such as cladribine (2-CdA), have been introduced in the 1990s. However,...
10.
Bohn J, Dietrich S
Cancers (Basel)
. 2022 Feb;
14(4).
PMID: 35205704
Classic hairy cell leukemia (HCL) is a rare indolent B-cell lymphoproliferative disorder characterized by profound pancytopenia and frequent infectious complications due to progressive infiltration of the bone marrow and spleen....